BTMD

biote said a voluntary recall of certain bioidentical hormone pellets in January created a temporary supply disruption that cut Q1 revenue by an estimated $1.7 million, added about $1.5 million of incremental costs, distracted the salesforce and reduced procedure volumes. Revenue fell 8.3% year-over-year to $44.9 million (procedure revenue down 13.2% to $31.3M) while dietary supplement sales grew 19.1% to $11.0M; gross margin slipped to 68.9% and adjusted EBITDA declined to $8.7M with net income of $2.7M ($0.06 EPS). Management expects supply to normalize as Asteria adds shifts and third-party partners fill orders, has expanded the salesforce and trained 200+ practitioners, and has maintained 2026 guidance of revenue above $190M and adjusted EBITDA greater than $38M while anticipating procedure revenue to return to growth in H2. Interested in biote Corp.? Here are five stocks we like better. biote (NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting procedure revenue, margins, and salesforce productivity while management works to restore supply continuity through its Asteria Health manufacturing operation and third-party partners. Chief Executive Officer Bret Christensen said the company voluntarily withdrew certain bioidentical hormone pellet inventory from the market in January “out of an abundance of caution.” He said the temporary supply disruption reduced first-quarter revenue by an estimated $1.7 million and led to about $1.5 million of incremental costs. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Christensen added that the recall became “a significant distraction” for the salesforce because representatives were “forced to service accounts versus focusing on growth.” While the company expects the impacts to continue into the second quarter, Christensen said management views the issue as temporary and not reflective of long-term demand trends. Chief Financial Officer Bob Peterson reported revenue decreased 8.3% year over year to $44.9 million. Procedure revenue declined 13.2% to $31.3 million, including the $1.7 million recall-related impact tied to hormone pellets shipped by Asteria Health. → Tyson Foods' Total Returns: Tasty Treats for Income Investors? Peterson attributed the decline...

Image source: The Motley Fool. Wednesday, May 6, 2026 at 5 p.m. ET Chief Executive Officer — Bret Christensen Chief Financial Officer — Bob Peterson Investor Relations — Szymon Serowiecki Operator: Good day, and welcome to the biote Corp. first quarter 2026 earnings conference call. All participants will be in listen-only mode. Please note this event is being recorded. I would now like to turn the conference over to Szymon Serowiecki, Investor Relations. Please go ahead. Szymon Serowiecki: Thank you for joining us today. This afternoon, biote Corp. published financial results for the first quarter ended 03/31/2026. This news release is available in the Investor Relations section of the company's website. Hosting today's call, Bret Christensen, Chief Executive Officer, and Bob Peterson, Chief Financial Officer. Before we get started, I would like to remind everyone that management may make statements during this call, including forward-looking statements regarding, among other things, the company's financial results, future performance, opportunities, business outlook, strategic plans, anticipated benefits, goals, future development, manufacturing and commercialization activities, its competitive position, and rigor across operations, benefits of its solutions, anticipated impacts of macroeconomic concerns on business results of operations, financial condition, and other matters that do not relate to historical facts. These statements are not guarantees of future performance and are subject to a variety of risks and uncertainties, some of which are beyond the company's control. Actual results could differ materially from expectations reflected in any forward-looking statements. These statements are based on management's current expectations as of today. biote Corp. undertakes no obligation to update them in the future. Therefore, these statements should not be relied upon as representing the company's views as of any subsequent date. For a discussion of risks and other important factors that could affect our actual results, please refer to our SEC filings available on the SEC's website and the Investor Relations section of our website, as well as risks and other important factors discussed in the earnings release. Management also refers to adjusted EBITDA and adjusted EBITDA margin, which are non-GAAP financial measures, to provide additional information to i...

biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.06, delivering a surprise of +20%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. biote Corp., which belongs to the Zacks Medical - Products industry, posted revenues of $44.94 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 2.71%. This compares to year-ago revenues of $48.99 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. biote Corp. shares have lost about 15% since the beginning of the year versus the S&P 500's gain of 6%. While biote Corp. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for biote Corp. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here....

Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% IRVING, Texas, May 06, 2026--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the first quarter ended March 31, 2026. "During the first quarter of 2026, we continued to advance our strategic priorities and remained focused on our key objective of restoring sustainable procedure revenue growth," said Bret Christensen, Biote’s Chief Executive Officer. "Leading indicators of future performance, including the number of newly trained practitioners and new clinic growth, are moving in the right direction, reinforcing our conviction in our strategic initiatives. We remain committed to investing in our commercial organization, and I am pleased to report we are nearing our stated goal of approximately 120 sales representatives." Mr. Christensen continued, "First quarter financial results were impacted by supply constraints related to the voluntary recall of certain hormone pellet products. We are increasing inventory levels to ensure continuity of care throughout our clinic network. We continue to emphasize consistent operational execution, supporting our growing network of practitioners and positioning the company for durable, long-term growth." 2026 First Quarter Financial Review (All financial result comparisons made are against the prior-year period unless otherwise noted) Total revenue was $44.9 million, a decrease of 8.3% from $49.0 million. Procedure revenue declined 13.2% to $31.3 million, and was impacted by the voluntary recall of certain hormone pellets shipped by Asteria Health. Dietary supplements revenue grew 19.1% to $11.0 million. Gross profit margin was 68.9%, as compared to 74.3%, as a result of impacts from the voluntary recall, which included the sourcing of rep...

Performance was primarily impacted by a voluntary recall of bio-identical hormone pellet inventory initiated in January, which created a $1.7 million revenue headwind. The recall acted as a significant operational distraction, forcing the sales force to focus on account servicing and inventory allocation rather than new growth initiatives. Management successfully expanded the sales team to approximately 120 personnel, completing a key 2026 strategic objective to increase commercial capacity. A more disciplined qualification process is shifting the sales pipeline toward higher-value OB/GYN and general practitioners to improve long-term revenue predictability. New practitioner training reached near-full capacity with over 200 trained in Q1, which management views as a leading indicator for future procedure volume. Vertical integration at Asteria Health was temporarily throttled, with the facility producing only 30% of shipped pellets in Q1 compared to over 50% in the prior quarter. Management maintains full-year 2026 guidance, expecting revenue above $190 million based on an anticipated return to growth in the second half of the year. Supply continuity at Asteria Health is expected to be fully restored by the end of the second quarter through the implementation of a second production shift. Procedure revenue growth for the first half of 2026 is now expected to be moderately lower than previously forecast due to lingering recall effects. The 200+ practitioners trained in Q1 are expected to begin contributing meaningfully to financial performance following a typical six-month onboarding ramp. Gross margins are expected to remain under pressure in Q2 due to an elevated mix of higher-cost third-party supply while Asteria builds safety stock. The voluntary recall resulted in approximately $1.5 million of incremental costs, including $1.1 million impacting gross profit and $0.4 million in SG&A. Cash and cash equivalents decreased to $5.3 million following the full repayment of share repurchase liabilities in January 2026. Inventory allocation measures currently limit customers to two or three weeks of supply, which may continue to impact practitioner scheduling confidence in the near term. Net income was impacted by a $2.1 million gain from the change in fair value of earn-out liabilities, significantly lower than the $10.7 million gain in the prior year period. Our...

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.04%. A quarter ago, it was expected that this medical technology company would post earnings of $1.43 per share when it actually produced earnings of $1.44, delivering a surprise of +0.7%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. GE HealthCare, which belongs to the Zacks Medical - Products industry, posted revenues of $5.13 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.52%. This compares to year-ago revenues of $4.78 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. GE HealthCare shares have lost about 16.5% since the beginning of the year versus the S&P 500's gain of 4.3%. While GE HealthCare has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for GE HealthCare was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of...

IRVING, Texas, April 22, 2026--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, found here, shortly after the event concludes. About Biote Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "may," "can," "should," "will," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "hope," "believe," "seek," "target," "continue," "could," "might," "ongoing," "potential," "predict," "would" and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics,...

Image source: The Motley Fool. Wednesday, March 11, 2026 at 5 p.m. ET Chief Executive Officer — Bret Christensen Chief Financial Officer — Bob Peterson Bret Christensen, Chief Executive Officer, and Bob Peterson, Chief Financial Officer. Before we get started, I would like to remind everyone that management statements during this call include forward-looking statements regarding, among other things, the company's financial results, future performance and growth opportunities, business outlook, strategic plans, anticipated benefits, goals, research and development, manufacturing and commercialization activities, its competitive position, regulatory process operations, benefits of its solutions, anticipated impact of macroeconomic conditions on the business, results of operations and financial conditions, and other matters that do not relate to historical facts. These statements are not guarantees of future performance. They are subject to a variety of risks and uncertainties, some of which are beyond the company's control. Actual results could differ materially from expectations reflected in any forward-looking. These statements are subject to risks, uncertainties, and assumptions that are based on management's current expectations as of today. biote Corp. undertakes no obligation to update them in the future. Therefore, statements should not be relied upon as representing the company's views as of any subsequent date. For discussion of risks and other important facts that could affect their actual results, please refer to our SEC filings available on the SEC's website and in the Investor Relations section of our website as well as risks and other important factors discussed in the earnings release. Management also refers to EBITDA and adjusted EBITDA margin, which are non-GAAP financial measures to provide additional information to investors. A reconciliation of the non-GAAP to GAAP measures is provided in our earnings release with the primary differences being stock-based compensation, fair value adjustments, certain liabilities, and other non-operating expenses. Please refer to our fourth quarter 2025 earnings release for a reconciliation of these non-GAAP measures to the most comparable GAAP measures. I will now turn the call over to Bret Christensen. Bret Christensen: Thank you, Szymon. Thank you all for joining us. I will provide a summary of our key st...

biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +20.00%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.22, delivering a surprise of +340%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. biote Corp., which belongs to the Zacks Medical - Products industry, posted revenues of $46.41 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.47%. This compares to year-ago revenues of $49.83 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. biote Corp. shares have lost about 34.6% since the beginning of the year versus the S&P 500's decline of 0.9%. While biote Corp. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for biote Corp. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy...

This article first appeared on GuruFocus. Release Date: March 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Biote Corp (NASDAQ:BTMD) successfully rebuilt a significant portion of its commercial team, increasing the number of salespeople from approximately 60 to over 90 by the end of 2025. The company reported a 16% growth in dietary supplement revenue, driven by the continued expansion of its e-commerce channel. Biote Corp (NASDAQ:BTMD) has seen an acceleration in the number of practitioners attending training sessions, indicating successful recruitment and training efforts. The company plans to expand its sales personnel to approximately 120 by the end of Q1 2026, reflecting a commitment to growth. Biote Corp (NASDAQ:BTMD) is investing in its technology platform to enhance the practitioner journey and improve long-term practitioner retention. Fourth quarter revenue decreased by 6.9%, with procedure revenue declining 13% due to lower net new clinic additions and procedure volume. Gross profit margin decreased from 71.8% to 68.0%, impacted by a $1.3 million charge to inventory related to a voluntary recall. The company experienced higher practitioner and clinic attrition rates, which were stable at around 5% but accelerated to high single-digits in 2025. Adjusted EBITDA decreased to $11.7 million with a margin of 25.2%, down from $15.1 million and a margin of 30.3% in the previous year. Biote Corp (NASDAQ:BTMD) anticipates a mid to high single-digit percentage decrease in procedure revenue in the first half of 2026, partly due to the recall impact. Warning! GuruFocus has detected 4 Warning Sign with BTMD. Is BTMD fairly valued? Test your thesis with our free DCF calculator. Q: What's your take on the FDA's removal of black box warnings for certain HRTs and how could this impact demand? Also, can you elaborate on the voluntary recall and any FDA feedback? A: Brett Christensen, CEO: The removal of the black box warning is a positive tailwind, indicating recognition of hormone optimization as a viable option. The recall was a voluntary action taken out of caution, and we are working closely with the FDA, ensuring communication and product replacement are handled effectively. Q: Can you explain the expected procedure revenue growth in the first half of 2026? Is it purely based on the number of proced...

During 2025, management rebuilt the commercial team, increasing sales personnel from approximately 60 to over 90 to address high clinic attrition, an initiative that began showing results in stabilizing the network by the fourth quarter. The company restructured its commercial organization by geographic region and sales role to bifurcate focus between servicing existing accounts and driving new clinic starts. Procedure revenue declines were primarily driven by higher-than-historical clinic attrition, which accelerated to high single digits in 2024 compared to the typical 5% rate. Strategic focus has shifted toward maximizing value from top-tier clinics by refining contract models and incentive structures to strengthen long-term practitioner retention. Operational discipline was enhanced through upgraded data analytics and internal systems, which management believes will enable more consistent execution and scalability. Dietary supplement growth of 16% served as a critical hedge, driven by e-commerce expansion and increased patient engagement with healthy aging solutions. Management expressed cautious optimism that the foundational work completed in 2025 has positioned the company to reaccelerate procedure revenue growth in the second half of 2026. Biote plans a significant step-up in operating expenses to expand the sales force further to approximately 120 personnel by the end of 2026. The company is prioritizing a 'leading-edge' technology platform investment to streamline the practitioner journey from initial certification to long-term clinic management. Financial guidance for 2026 assumes a mid to high single-digit decrease in procedure revenue for the full year, though management expects a return to year-over-year growth by the second half. The 2026 outlook includes a forecasted revenue of above $190,000,000 and adjusted EBITDA exceeding $38,000,000, accounting for the near-term impact of planned investments. Management anticipates dietary supplement revenue will continue to grow at a mid to high single-digit rate, supported by the new technology platform's cross-selling capabilities. A $1,300,000 inventory charge was recorded in 2025 due to a voluntary recall of specific hormone pellet lots shipped by Asteria Health. Management flagged a potential near-term headwind to gross margins if the product mix shifts toward more expensive third-party manufacturi...